Investing.com - Cerevel Therapeutics Holdings reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Cerevel Therapeutics Holdings announced earnings per share of $-0.66 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.62 on revenue of $0.00.
Cerevel Therapeutics Holdings 's are down 27% and is trading at $25.17 , still down 45.47% from its 52 week high of $46.16 set on Monday, November 8, 2021.
Cerevel Therapeutics Holdings shares lost 7.16% to trade at $25.17 in intra-day trade the report.
Cerevel Therapeutics Holdings follows other major Healthcare sector earnings this month
Cerevel Therapeutics Holdings's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar